
Evolvere BioSciences
Evolvere BioSciences is a YC Summer 2024 (S24) company. Based in Oxford, England, United Kingdom. Team of 3.
About Evolvere BioSciences
Summary
Evolvere BioSciences develops antibiotics designed to stay effective as bacteria evolve, using AI models trained on co-evolutionary protein-protein interaction data to anticipate and outpace bacterial mutations. The drugs precisely target pathogenic bacteria while leaving beneficial microbes and human cells unharmed. This approach replaces the recurring cycle of developing new antibiotics in response to resistance, a cycle driven by the failure of conventional drugs that bacteria can eventually overcome.
Go-to-market
The primary customers are healthcare systems, hospitals, and pharmaceutical partners facing drug-resistant bacterial infections, a problem that already outpaces malaria and AIDS in mortality.
From the Y Combinator listing
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.
Facts
- Healthcare / Healthcare -> Therapeutics
- Oxford, England, United Kingdom
- 3
- Active
- Early
Founders (3)
- Adam Winnifrith
- Piotr Jedryszek
- Weronika Slesak
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works